STOCK TITAN

LIGAND PHARMACEUTICALS (LGNDZ) SEC Filings

LGNDZ OTC
Rhea-AI Summary

John W. Kozarich, a director of Ligand Pharmaceuticals Inc. (LGND), sold 500 shares of common stock at $325 per share on November 12, 2026. He directly held 42,122 shares after the sale. The transaction was made under a written Rule 10b5-1 trading plan adopted August 12, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Jason Aryeh, a director of Ligand Pharmaceuticals Inc. (LGND), reported six direct sales of common stock on November 10, 2026, totaling 3,000 shares. The six reported prices were $319.9900, $319.9950, $320.0000, $320.0200, $320.1000 and $320.2000 per share; no Rule 10b5-1 plan is reported for the sales. Separately, 8,000 shares are listed as indirectly held by certain funds managed by JALAA Equities, LP, JLV Investments, LP and affiliates. Aryeh may be deemed a beneficial owner of those shares under Rule 16a-1.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Ligand Pharmaceuticals Inc. director Martine Zimmermann filed a notice covering a proposed sale of 2,000 common shares, with an aggregate market value of $636,336.20 and an approximate sale date of November 12, 2026. The notice lists 20,002,986 common shares outstanding. It also reports that Zimmermann sold 1,200 common shares on September 10, 2026, for gross proceeds of $342,000.00 during the preceding three months.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
Rhea-AI Summary

LGND director John Kozarich reported a proposed sale of 500 common shares, with an aggregate market value of $162,500 and an approximate sale date of November 12, 2026; UBS Financial Services, Inc. is named as broker. August 12, 2026 is listed as the plan adoption or instruction date if relying on Rule 10b5-1. Kozarich also sold 500 shares on November 11, 2026, for gross proceeds of $158,658 during the past three months. The acquisition history lists issuer stock awards of 250 shares dated February 28, 2022, and another 250 shares dated June 6, 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
-
Rhea-AI Summary

John Kozarich, a director of Ligand Pharmaceuticals Inc. (LGND), reported a proposed sale of 500 common shares with an aggregate market value of $158,659.25. The notice lists UBS Financial Services, Inc. as broker and an approximate sale date of November 11, 2026. Kozarich acquired 250 shares through a stock award on May 25, 2018 and another 250 through a stock award on June 6, 2025. It lists August 12, 2026 as the date of plan adoption or giving of instruction, if relying on Rule 10b5-1.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
-
Rhea-AI Summary

Ligand Pharmaceuticals Inc. (LGND) reported that Invesco Ltd., as a parent holding company to its investment advisers, may be deemed to beneficially own 1,520,911 common shares, or 7.6% of the class, as of September 30, 2026. The shares are held of record by Invesco clients. Invesco reported sole voting power over 1,497,232 shares and sole dispositive power over 1,520,911 shares, with no shared voting or dispositive power. Invesco stated that no one person has greater than 5% economic ownership in the reported securities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
ownership
Rhea-AI Summary

Ligand Pharmaceuticals Inc. director Jason Aryeh filed notice of a proposed sale of 3,000 shares of Class B common, with an approximate sale date of November 10, 2026. The notice lists an aggregate market value of $960,084.19 for the shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
-
Rhea-AI Summary

Jason Aryeh, a director of Ligand Pharmaceuticals Inc. (LGND), sold 282 common shares on November 4, 2026, at $319.99 per share. He reported 108,476 shares held directly after the sale. Separately, funds managed by JALAA Equities, LP, JLV Investments, LP, and affiliates held 8,000 shares indirectly; Aryeh is a general partner of JALAA Equities and a partner of JLV Investments. No Rule 10b5-1 plan is reported.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Ligand Pharmaceuticals Inc (LGND) director Jason Aryeh reported a proposed sale of 282 Class B common shares, with an aggregate market value of $90,225.50. The notice lists Nasdaq as the exchange and November 4, 2026, as the approximate sale date.

The notice identifies the shares as a secondary-market purchase and remarks that they were acquired between May 14, 2019, and July 30, 2019. It also lists prior sales by Aryeh: 1,209 shares for $385,185.47 and 202 shares for $64,738.00 on October 30, 2026, and 700 shares for $221,595.09 on November 2, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
Rhea-AI Summary

Andrew Reardon, Ligand Pharmaceuticals’ CLO & Secretary, exercised employee stock options for 5,000 common shares at a $52.27 exercise price on November 2, 2026, and sold 5,000 shares across 13 reported sales. The transactions were made under a written Rule 10b5-1 trading plan adopted June 4, 2026. Reardon held 24,104 employee stock options following the exercise.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider

FAQ

How many LIGAND PHARMACEUTICALS (LGNDZ) SEC filings are available on StockTitan?

StockTitan tracks 93 SEC filings for LIGAND PHARMACEUTICALS (LGNDZ), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for LIGAND PHARMACEUTICALS (LGNDZ)?

The most recent SEC filing for LIGAND PHARMACEUTICALS (LGNDZ) was filed on November 16, 2026.